ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pegloticase

Also written as “pegloticase”, “Pegloticase with MTX” and “Puricase”.

Its studies are mostly in Gout · Renal Insufficiency, Chronic, led by 3 companies.

Drug pagePegloticase: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 9, 201814 company-led studies, 1 open or runningNext primary completion: Jun 18, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only81 open or runningphase 4since Aug 9, 2018Aug 9, 2018Jun 18, 2028phase 3 · NCT07388498
Savient Pharmaceuticals50 open or runningphase 3since May 10, 2006Mar 24, 2004none ahead
Ampel BioSolutionsits history only10 open or runningphase 2since Oct 30, 2015Oct 30, 2015none ahead

Also a collaborator on its studies: IND 2 Results.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Savient Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2004First study: phase 2 study in GoutFirst studyNCT00080210 · 40 enrolled · United States
  2. May 10, 2006Phase 3 study in GoutNCT00325195 · 225 enrolled · United States, Canada, Mexico
  3. May 6, 2008Phase 3 study in GoutNCT00675103 · 7 enrolled · United States
  4. Oct 27, 2008Phase 3 study in GoutNCT01356498 · 151 enrolled · United States
  5. Nov 29, 2012Phase 1 study in Renal Insufficiency, ChronicNCT01739660 · 12 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 Savient Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01739660Renal Insufficiency, Chronic · United States1CompletedApr 201312
NCT01356498Gout · United States3CompletedJan 2010151
NCT00675103Gout · United States3CompletedJan 20097
NCT00325195Gout · United States, Canada, Mexico3CompletedOct 2007225
NCT00080210Gout · United States2Completed40

How it is read

Names in the registry

  • “Pegloticase”, 9 entries
  • “pegloticase”, 2 entries
  • “Pegloticase with MTX”, 1 entry
  • “Puricase”, 1 entry
  • “pegloticase 8 mg i.v.”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.